Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-negative Breast Cancer × sacituzumab govitecan × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Triple Negative Breast Neoplasms 28 Neoplasm Metastasis 5 Endometrial Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Brain Neoplasms 2 Advanced Breast Cancer 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Locally Advanced Non-resectable Breast Cancer 1 Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Neoplasm, Residual 1 Meningeal Carcinomatosis 1 HER2-negative Breast Cancer 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡